Posted on Wednesday 25 January 2017 by ub digital
Cirdan Imaging chief executive Hugh Cormican and Invest NI chief executive Alastair Hamilton
A medical technology company from Lisburn is creating 46 new jobs to help it target overseas markets and boost its research and development capabilities.
Cirdan Imaging develops medical devices and software used in surgery and cancer diagnosis by pathologists and radiologists and is targeting both public and private hospital laboratories.
The jobs offer an above-average salary of £33,500 a year and will be filled over the next four years, Hugh Cormican, CEO of Cirdan Imaging, said.
He wants the company to lead the way in the transformation of labs in the next few years.
“Hospital laboratories are undergoing a major transformation as they adopt the new workflows and instrumentation required for the emerging precision medicine model of HealthCare. Working with QUB, we intend to be at the forefront of this change, supporting laboratories globally to meet this demand.”
He said the new roles will be outward facing.
“The new jobs will help us identify new markets and new customers, and our R&D investment will mean we can develop new products and expand our exports especially into the markets of Oceania and North America. The support of Invest NI has been invaluable to allow us to make the necessary scale of investment within the required timescales to allow us to compete effectively in these markets.”
Mr Cormican is one of the founders of Andor Technologies, the highly successful scientific camera maker which was sold to Oxford Instruments.
Invest NI has offered £1.4m in support towards the R&D project and the creation of the 46 jobs, offering an average salary of £33,500. The R&D project is in collaboration with the Northern Ireland’s Molecular Pathology Laboratory (NIMPL) at Queens University Belfast (QUB).
Invest NI CEO, Alastair Hamilton said the research and development aspect of the investment is key.
“Studies show a solid link between investment in R&D, profitability and growth. This R&D project will enable Cirdan to develop new precision medicine product solutions to meet the future need of both existing and new customers.”